Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
about
Natural products as aromatase inhibitorsPELP1: A novel therapeutic target for hormonal cancersTargeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancerSignificance of ER-Src axis in hormonal therapy resistancePathways to tamoxifen resistance.Cellular targets of estrogen signaling in regeneration of inner ear sensory epithelia.Regulation of hormonal therapy resistance by cell cycle machinery.Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.Role of estrogen receptor signaling in breast cancer metastasis.Estrogen Enhances the Cell Viability and Motility of Breast Cancer Cells through the ERα-ΔNp63-Integrin β4 Signaling Pathway.Alternatively spliced tissue factor synergizes with the estrogen receptor pathway in promoting breast cancer progression.Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens.Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.Aromatase inhibitors in post-menopausal metastatic breast carcinoma.Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer.The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer.The crossroads of breast cancer progression: insights into the modulation of major signaling pathways.
P2860
Q24620153-4666672E-F9C3-40E7-B0E3-A22282B0B3B4Q28267811-050C03BF-1FB5-4EAF-95E0-C2AFCAEB4BD7Q28271388-A3A715FC-1925-44E8-8AB0-1CD19A6DE1E9Q28301805-ADAA3E37-E2FA-4498-8D3D-10942CBC20CFQ30441001-9A3EEA7B-62F3-410A-8373-7792E1A9C716Q30478755-06F5BD47-9D50-403D-B98B-9C3854D6BE06Q33635621-EA8CAE4F-43B7-44AB-9650-7BACD18E08FEQ35584560-A8E9D98B-B762-4F45-B95D-F8798C344223Q35684545-1B6CB6C9-4802-4BE7-A0B5-353FB10F57B4Q35914389-6D25AC5F-F649-42B4-BFC3-D5D5800FB4CBQ36030868-C816D446-E059-437E-A45A-7DB8360BED75Q36646986-F81C5B55-B28F-47F8-9388-50FE5A98CBF0Q36742629-3F18442B-308B-4FC3-81A1-186F11139489Q36861597-1B65D246-8DC1-42FF-AFE2-621C850E10A1Q36950482-9D1FD3BD-63D8-450A-B38F-61D9EC1C4329Q36955067-7EBE46B9-E377-4D7E-B5F9-192E1B61FDC0Q37570653-77459BCA-DC51-40E9-A56C-7824C81D6A40Q47167746-C5130184-2FC1-477E-8082-57668642FF3A
P2860
Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
@ast
Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
@en
type
label
Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
@ast
Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
@en
prefLabel
Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
@ast
Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
@en
P2860
P921
P356
P1476
Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603316
P407
P577
2006-08-22T00:00:00Z